JP2012526852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526852A5 JP2012526852A5 JP2012511052A JP2012511052A JP2012526852A5 JP 2012526852 A5 JP2012526852 A5 JP 2012526852A5 JP 2012511052 A JP2012511052 A JP 2012511052A JP 2012511052 A JP2012511052 A JP 2012511052A JP 2012526852 A5 JP2012526852 A5 JP 2012526852A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- genotype
- promoter gene
- agent
- result
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 39
- 101000585693 Homo sapiens Mitochondrial 2-oxodicarboxylate carrier Proteins 0.000 claims 13
- 101001041245 Homo sapiens Ornithine decarboxylase Proteins 0.000 claims 13
- 102100021079 Ornithine decarboxylase Human genes 0.000 claims 13
- 108700028369 Alleles Proteins 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 10
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 8
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 8
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims 4
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 229920000768 polyamine Polymers 0.000 claims 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 4
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 4
- 229960000894 sulindac Drugs 0.000 claims 4
- VLCYCQAOQCDTCN-ZCFIWIBFSA-N α-difluoromethylornithine Chemical group NCCC[C@@](N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-ZCFIWIBFSA-N 0.000 claims 4
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims 3
- 208000003200 Adenoma Diseases 0.000 claims 2
- 208000004804 Adenomatous Polyps Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 108020002494 acetyltransferase Proteins 0.000 claims 2
- 102000005421 acetyltransferase Human genes 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 229940111134 coxibs Drugs 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 229940063673 spermidine Drugs 0.000 claims 2
- 229940063675 spermine Drugs 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21621609P | 2009-05-14 | 2009-05-14 | |
| US61/216,216 | 2009-05-14 | ||
| US21768209P | 2009-06-03 | 2009-06-03 | |
| US21767909P | 2009-06-03 | 2009-06-03 | |
| US61/217,682 | 2009-06-03 | ||
| US61/217,679 | 2009-06-03 | ||
| PCT/US2010/034974 WO2010132817A1 (en) | 2009-05-14 | 2010-05-14 | Carcinoma diagnosis and treatments, based on odc1 genotype |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015213116A Division JP2016074672A (ja) | 2009-05-14 | 2015-10-29 | Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526852A JP2012526852A (ja) | 2012-11-01 |
| JP2012526852A5 true JP2012526852A5 (enExample) | 2013-06-27 |
| JP6083860B2 JP6083860B2 (ja) | 2017-02-22 |
Family
ID=43085356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511052A Expired - Fee Related JP6083860B2 (ja) | 2009-05-14 | 2010-05-14 | Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療 |
| JP2015213116A Pending JP2016074672A (ja) | 2009-05-14 | 2015-10-29 | Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015213116A Pending JP2016074672A (ja) | 2009-05-14 | 2015-10-29 | Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US8329636B2 (enExample) |
| EP (1) | EP2430452B1 (enExample) |
| JP (2) | JP6083860B2 (enExample) |
| CN (1) | CN102483415B (enExample) |
| AU (1) | AU2010248803B2 (enExample) |
| CA (1) | CA2761946A1 (enExample) |
| DK (1) | DK2430452T3 (enExample) |
| ES (1) | ES2507145T3 (enExample) |
| HR (1) | HRP20140887T1 (enExample) |
| IL (1) | IL216369B (enExample) |
| PL (1) | PL2430452T3 (enExample) |
| PT (1) | PT2430452E (enExample) |
| SI (1) | SI2430452T1 (enExample) |
| SM (1) | SMT201400177B (enExample) |
| WO (1) | WO2010132817A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2430452E (pt) | 2009-05-14 | 2014-09-30 | Univ Arizona State | Diagnóstico e tratamentos de carcinoma com base no genótipo odc1 |
| CA2799431A1 (en) * | 2010-05-14 | 2011-11-17 | Cancer Prevention Pharmaceuticals, Inc. | Cancer prevention and treatment methods based on dietary polyamine content |
| WO2012088146A2 (en) * | 2010-12-20 | 2012-06-28 | The University Of Notre Dame | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease |
| US20120172244A1 (en) | 2010-12-20 | 2012-07-05 | Steven Buechler | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease |
| LT2912193T (lt) * | 2012-10-29 | 2018-12-27 | Arizona Board Of Regents On Behalf Of University Of Arizona | Prognozuojami žymenys, skirti vėžio terapijoms poliamino inhibitoriumi |
| WO2015195120A1 (en) * | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
| US20190046484A1 (en) * | 2015-02-12 | 2019-02-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating neuroblastoma |
| CA2980078C (en) * | 2015-03-16 | 2024-03-12 | Personal Genome Diagnostics Inc. | Systems and methods for analyzing nucleic acid |
| MX390899B (es) | 2015-10-30 | 2025-03-21 | Cancer Prevention Pharmaceuticals Inc | Formulación de combinación de dosis fija, eflornitina y sulindaco. |
| WO2017075576A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
| JP6963271B2 (ja) * | 2017-01-20 | 2021-11-05 | 国立大学法人東海国立大学機構 | イヌの遺伝性消化管腫瘍症の遺伝子診断法 |
| CN114096240A (zh) | 2019-05-17 | 2022-02-25 | 癌症预防制药股份有限公司 | 用于治疗家族性腺瘤性息肉病的方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654349A (en) | 1970-05-01 | 1972-04-04 | Merck & Co Inc | Substituted indenyl acetic acids |
| US3647858A (en) | 1970-05-01 | 1972-03-07 | Merck & Co Inc | Process for preparing 1-benzylidene-3-indenyl acetic acids |
| US4413141A (en) | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
| US4330559A (en) | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
| BR8108820A (pt) | 1980-09-24 | 1982-08-24 | Cetus Corp | Processo e sonda de diagnostico |
| ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4859452A (en) | 1986-01-17 | 1989-08-22 | Board Of Regents, The University Of Texas System | Methods for the reduction of difluoromethylornithine associated toxicity |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US4925835A (en) | 1986-05-01 | 1990-05-15 | Sloan-Kettering Institute For Cancer Research | Aziridinyl putrescine containing compositions and their uses in treating prostate cancer |
| US5002879A (en) | 1986-05-06 | 1991-03-26 | Merrell Dow Pharmaceuticals | Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| FR2706255B1 (fr) | 1993-06-17 | 1995-10-27 | Univ Rennes | Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques. |
| WO1995021271A1 (en) | 1994-02-07 | 1995-08-10 | Molecular Tool, Inc. | Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis |
| US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
| EP1067919A1 (en) | 1998-03-28 | 2001-01-17 | THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA | Dfmo and sulindac combination in cancer chemoprevention |
| US7700568B2 (en) * | 1998-06-30 | 2010-04-20 | Sloan-Kettering Institute For Cancer Research | Uses of DNA-PK |
| JP2002533404A (ja) * | 1998-12-23 | 2002-10-08 | ジー・ディー・サール・アンド・カンパニー | 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法 |
| US6753422B2 (en) | 1999-03-01 | 2004-06-22 | O'brien Thomas G. | Odc allelic analysis method for assessing carcinogenic susceptibility |
| US6573290B1 (en) | 1999-05-17 | 2003-06-03 | Ilex Oncology, Inc. | DFMO and celecoxib in combination for cancer chemoprevention and therapy |
| US6602910B2 (en) | 2000-03-07 | 2003-08-05 | Ilex Oncology, Inc. | D-enantiomer of DFMO and methods of use therefor |
| WO2001068076A2 (en) | 2000-03-07 | 2001-09-20 | Ilex Oncology, Inc. | D-enantiomer of dfmo and methods of use thereof for treating cancer |
| JP2004506683A (ja) | 2000-08-24 | 2004-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | α−ジフルオロメチルオルニチン（ＤＦＭＯ）は、ヒト前立腺におけるポリアミンレベルを抑制する |
| US7273888B2 (en) | 2001-11-16 | 2007-09-25 | Als Therapy Development Foundation, Inc. | Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis |
| US9072778B2 (en) | 2005-12-20 | 2015-07-07 | University Of Hawaii | Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors |
| US8283331B2 (en) | 2007-10-09 | 2012-10-09 | Children's Medical Center Corporation | Methods to regulate miRNA processing by targeting Lin-28 |
| WO2010077653A2 (en) | 2008-12-08 | 2010-07-08 | The Procter & Gamble Company | Personal care composition in the form of an article having a hydrophobic surface-resident coating |
| PT2430452E (pt) | 2009-05-14 | 2014-09-30 | Univ Arizona State | Diagnóstico e tratamentos de carcinoma com base no genótipo odc1 |
| CA2799431A1 (en) | 2010-05-14 | 2011-11-17 | Cancer Prevention Pharmaceuticals, Inc. | Cancer prevention and treatment methods based on dietary polyamine content |
| LT2912193T (lt) | 2012-10-29 | 2018-12-27 | Arizona Board Of Regents On Behalf Of University Of Arizona | Prognozuojami žymenys, skirti vėžio terapijoms poliamino inhibitoriumi |
-
2010
- 2010-05-14 PT PT107756264T patent/PT2430452E/pt unknown
- 2010-05-14 PL PL10775626T patent/PL2430452T3/pl unknown
- 2010-05-14 WO PCT/US2010/034974 patent/WO2010132817A1/en not_active Ceased
- 2010-05-14 CA CA2761946A patent/CA2761946A1/en not_active Abandoned
- 2010-05-14 EP EP10775626.4A patent/EP2430452B1/en active Active
- 2010-05-14 CN CN201080031983.5A patent/CN102483415B/zh not_active Expired - Fee Related
- 2010-05-14 AU AU2010248803A patent/AU2010248803B2/en not_active Ceased
- 2010-05-14 JP JP2012511052A patent/JP6083860B2/ja not_active Expired - Fee Related
- 2010-05-14 HR HRP20140887AT patent/HRP20140887T1/hr unknown
- 2010-05-14 US US12/780,592 patent/US8329636B2/en active Active
- 2010-05-14 DK DK10775626.4T patent/DK2430452T3/da active
- 2010-05-14 SI SI201030738T patent/SI2430452T1/sl unknown
- 2010-05-14 ES ES10775626.4T patent/ES2507145T3/es active Active
-
2011
- 2011-11-14 IL IL216369A patent/IL216369B/en active IP Right Grant
-
2012
- 2012-12-10 US US13/709,753 patent/US9121852B2/en active Active
-
2014
- 2014-11-21 SM SM201400177T patent/SMT201400177B/xx unknown
-
2015
- 2015-09-01 US US14/841,750 patent/US9937141B2/en active Active
- 2015-10-29 JP JP2015213116A patent/JP2016074672A/ja active Pending
-
2018
- 2018-02-23 US US15/904,153 patent/US20190038584A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526852A5 (enExample) | ||
| Tan et al. | Optimizing pain management to facilitate enhanced recovery after surgery pathways | |
| Pergolizzi et al. | The pharmacological management of dental pain | |
| Sim et al. | Prospective randomized, double‐blind, placebo‐controlled study of pre‐and postoperative administration of a COX‐2‐specific inhibitor as opioid‐sparing analgesia in major colorectal surgery | |
| van der Heijde et al. | Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty‐two–week, randomized, controlled study | |
| Young et al. | Recent advances in multimodal analgesia | |
| Joffe et al. | Evaluation and treatment of pain in critically ill adults | |
| CY1110495T1 (el) | Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα | |
| Lotia et al. | New and emerging medical therapies in Parkinson’s disease | |
| Minkowitz et al. | Sufentanil sublingual tablet 30 mcg for the management of pain following abdominal surgery: A randomized, placebo‐controlled, phase‐3 study | |
| Viscusi et al. | Peripherally acting mu-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability | |
| Stasiowska et al. | Postoperative pain management | |
| Zeidan et al. | Median effective dose (ED50) of paracetamol and morphine for postoperative pain: a study of interaction | |
| Bhaskar et al. | Comparison of transdermal diclofenac patch with oral diclofenac as an analgesic modality following multiple premolar extractions in orthodontic patients: a cross over efficacy trial | |
| Malan Jr et al. | The cyclooxygenase-2-specific inhibitor parecoxib sodium is as effective as 12 mg of morphine administered intramuscularly for treating pain after gynecologic laparotomy surgery | |
| JP2018507910A5 (enExample) | ||
| Daniels et al. | Analgesic efficacy and safety of a novel injectable formulation of diclofenac compared with intravenous ketorolac and placebo after orthopedic surgery: a multicenter, randomized, double-blinded, multiple-dose trial | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| Douzjian et al. | Old drug, new route: a systematic review of intravenous acetaminophen after adult cardiac surgery | |
| Seeberger et al. | Carbidopa levodopa enteral suspension | |
| Nishimoto | OFIRMEV: an old drug becomes new again | |
| Bodnar | The use of propofol for continuous deep sedation at the end of life: a definitive guide | |
| Al Dakheel et al. | Emerging drugs for levodopa-induced dyskinesia | |
| Chung et al. | Long‐term follow‐up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension |